Evotec have forged a new drug discovery alliance with LEO Pharma focussed on dermatological conditions.
The aim is to generate new leads against innovative targets for a range of dermatological conditions and initially runs for two years. Financial details were not disclosed.
The collaboration leverages Evotec’s hit identification platform including the extensive screening, structural biology and fragment-based drug design capabilities and expertise together with LEO Pharma’s 110-year track record of drug development and advancing science in dermatology.
Evotec’s integrated discovery scientists will work in a joint team with scientists from LEO Pharma. The alliance will receive further support with high-value drug development and discovery ADME-Tox services.
Evotec COO Dr Mario Polywka, said: “Working together, we are convinced we will find innovative therapeutic approaches to dermatological conditions with a high unmet medical need.”
Dr Thorsten Thormann, Vice President, Research at LEO Pharma, added: “We are confident that our alliance with Evotec will further strengthen our research and help us expedite the discovery of novel small molecule therapeutics for skin diseases, for which there are large unmet medical needs, thus helping even more patients in the future.”